ESR1 and neoplasm: While ER-positive the second positive should be deleted tumours receive hormone therapies [2] and HER2-positive cancers receive targeted therapies such as trastuzumab and lapatinib [3], 'triple negative' cancers lacking these markers currently have no targeted therapies and cause a disproportionate number of breast cancer deaths [4].